MFG
CPRX

Merit Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Merit Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$868K Sell
27,613
-782
-3% -$23.1K 0.01% 1157
2026
Q1 		$703K Buy
28,395
+394
+1% +$9.39K 0.01% 1169
2025
Q4 		$654K Buy
+28,001
New +$624K 0.01% 1139

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Merit Financial Group's CPRX Position: Q2 2026 in Review

Merit Financial Group reduced its Catalyst Pharmaceutical (CPRX) stake by 2.8% in Q2 2026, selling an estimated $23.1K and leaving 27,613 shares worth $868K. The position accounts for 0.01% of the portfolio, ranked #1157.

Merit Financial Group first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Merit Financial Group held 27,613 shares of Catalyst Pharmaceutical worth $868K as of Q2 2026.
  • Merit Financial Group sold 782 Catalyst Pharmaceutical shares in Q2 2026, an estimated $23.1K.
  • Catalyst Pharmaceutical made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #1157 holding.
  • Merit Financial Group first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.